Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024 07:00 ET
|
Aclarion, Inc.
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare...
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
September 10, 2024 06:57 ET
|
Aclarion, Inc.
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial...
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
September 05, 2024 06:57 ET
|
Aclarion, Inc.
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population ...
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
August 13, 2024 09:07 ET
|
Aclarion, Inc.
Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private...
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
July 09, 2024 07:00 ET
|
Aclarion, Inc.
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care...
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
June 26, 2024 08:30 ET
|
Aclarion, Inc.
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
June 25, 2024 08:30 ET
|
Aclarion, Inc.
Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract...
Chronic Lower Back Pain Treatment Market Size to Surpass USD 4.52 Billion by 2030, exhibiting a CAGR of 9.5%
July 31, 2023 05:25 ET
|
Fortune Business Insights
Pune, India, July 31, 2023 (GLOBE NEWSWIRE) -- The chronic lower back pain treatment market size was valued at USD 2.21 billion in 2022 and is projected to reach a valuation of USD 2.40 billion in...
Chronic Lower Back Pain Treatment Market Size [2022-2028] | Industry Share, Growth, Trends, Revenue, Competitive Landscape, Forecast Report
January 10, 2022 04:51 ET
|
Fortune Business Insights
Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The rising prevalence of chronic pain across the world is expected to drive the global chronic lower back pain treatment market. As per the National...
Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain
August 19, 2021 02:00 ET
|
Persica Pharmaceuticals
Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populationsFirst...